Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia
Authors not listed
Taipei Medical University WanFang Hospital · 2022
Abstract
Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Anonymous. (2022). A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia. <em>Taipei Medical University WanFang Hospital</em>. https://clinicaltrials.gov/study/NCT05623852
Vancouver
Anonymous. A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia. Taipei Medical University WanFang Hospital. 2022.
BibTeX
@misc{anon2022APhase,
title = {A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia},
author = {Anonymous},
journal = {Taipei Medical University WanFang Hospital},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2013
Open access · OA
Murine models of atrophy, cachexia, and sarcopenia in skeletal muscle
American Journal of Clinical Nutrition 2010
Open access · OA
Skeletal muscle loss: cachexia, sarcopenia, and inactivity
Journal of Geriatric Oncology 2018
Preprint · OA
Sarcopenia & aging in cancer
Experimental Gerontology 2005
Citation only
Apoptosis in muscle atrophy: Relevance to sarcopenia
Merck Sharp & Dohme LLC 2007
Open access · US-GOV
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients With Sarcopenia
Biogerontology 2021
Citation only